Biotech Earnings: Tenax, ADC, and Rapport Report FY 2025 Results

The simultaneous release of full-year 2025 financial results from Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics provides a comprehensive look at the current state of the mid-cap biotechnology sector. As these companies transition from early-stage discovery into late-stage clinical execution and commercialization, the market is closely watching their ability to manage cash burn while hitting critical regulatory milestones. For Tenax Therapeutics, the focus remains squarely on the advancement of TNX-103 (levosimendan) for the treatment of pulmonary hypertension in patients with heart failure with preserved ejection fraction (PH-HFpEF). This condition represents a significant unmet medical need with no currently approved therapies, positioning Tenax as a potential first-mover in a high-value cardiovascular niche. The company’s corporate update emphasized the progress of its Phase 3 LEVEL study, which is the primary driver of its valuation heading into 2026.

ADC Therapeutics continues to navigate the complex commercial landscape for Zynlonta (loncastuximab tesirine) in the diffuse large B-cell lymphoma (DLBCL) market. The 2025 operational update highlighted the company's efforts to expand Zynlonta’s reach into earlier lines of therapy through the LOTIS-5 and LOTIS-7 trials. For ADC, the challenge is twofold: maintaining revenue growth for its lead product while simultaneously advancing its next-generation antibody-drug conjugate (ADC) pipeline, including ADCT-601 targeting AXL. The company's financial results reflect the high costs associated with late-stage oncology trials, but management has signaled a disciplined approach to capital allocation, prioritizing the most promising clinical assets to ensure a sustainable path to profitability.

“

The simultaneous release of full-year 2025 financial results from Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics provides a comprehensive look at the current state of the mid-cap biotechnology sector.

Rapport Therapeutics, a more recent entrant to the public markets compared to its peers in this cluster, provided a business update centered on its precision neuroscience platform. The company’s lead candidate, RAP-219, is being developed for focal epilepsy and other neurological disorders by targeting AMPA receptor-associated proteins. Rapport’s 2025 results highlight the successful completion of early-phase trials and the initiation of broader Phase 2 studies. As a company focused on neuromodulators, Rapport represents a broader trend in the industry toward more targeted, site-specific neurological treatments that aim to reduce the systemic side effects common in traditional CNS drugs.